DIGITAL EVENT
Thursday, June 9, 2022 | 8.30 AM - 2.50 PM (EST)
8:30 am Online Registration
8:30 am Online Registration
9:25 am Chair’s Opening Remarks
9:25 am Chair’s Opening Remarks
Weighing the Benefit-Risk: Reviewing How We Measure Safety Against Practicality
Weighing the Benefit-Risk: Reviewing How We Measure Safety Against Practicality
9:30 am Ruxolitinib and Baricitinib Impair Glycoprotein-VI Mediated Platelet Function
9:30 am Ruxolitinib and Baricitinib Impair Glycoprotein-VI Mediated Platelet Function
Synopsis
- Platelets express all the Janus kinases and several STAT proteins.
- JAK/STAT5 pathways are activated following stimulation of glycoprotein VI with collagen in platelets.
- Ruxolitinib and baricitinib impair platelet granule secretion, adhesion, and aggregation following stimulation with collagen.
10:00 am PANEL DISCUSSION: The JAK Class Black Box Warning: The Implications for the JAK Inhibitor Drug Development Landscape for Dermatology & Beyond
10:00 am PANEL DISCUSSION: The JAK Class Black Box Warning: The Implications for the JAK Inhibitor Drug Development Landscape for Dermatology & Beyond
Synopsis
- Cataloguing the implications across numerous disciplines the FDA issued JAK black box warning will have just as pharma was beginning to realise the potential the JAK/STAT pathway holds.
- Evaluating where the community sees the market potential for JAK inhibitors within the pharmaceutical industry despite the warning.
- Discussing ways in which companies may begin marketing their JAK inhibitors whilst also debating the demand for novel therapeutic options in underserved indications, where benefit-risk calculations must take place.
10:45 am
Morning Break & Speed Networking
10:45 am
Morning Break & Speed Networking
Exploring JAK Selectivity in the Push Towards Precise Medical Approaches
Exploring JAK Selectivity in the Push Towards Precise Medical Approaches
11:15 am Balancing Benefit/Risk in the Dermatology Disease Space
11:15 am Balancing Benefit/Risk in the Dermatology Disease Space
Synopsis
- Considering whether the black box warning will stifle innovation across the JAK inhibitor class
- Correlating disease severity and quality of life with off-target effects of JAK inhibitors
- Rethinking how we define the black box warning to patients
11:45 am The Journey to JAKs: First-in-Class Drugs to Treat Alopecia Areata
11:45 am The Journey to JAKs: First-in-Class Drugs to Treat Alopecia Areata
Synopsis
- Overviewing the science that provided the rationale for JAK inhibitors in Alopecia Areata
- Discussing biomarkers of treatment response and patient selection
- Looking ahead to the next-generation JAK inhibitors in Alopecia Areata
12:15 pm
Lunch Break
12:15 pm
Lunch Break
Future Horizons: Looking Ahead to Best Prepare Your JAK Inhibitor Pipelines
Future Horizons: Looking Ahead to Best Prepare Your JAK Inhibitor Pipelines
1:15 pm Revolutionizing Translational Modeling with 3D Technology
1:15 pm Revolutionizing Translational Modeling with 3D Technology
Synopsis
- Introducing the capabilities of the Tissue Bioprinting Lab at NCATS
- Championing 3D vascularized barrier tissue models with relevant disease models
- Relaying the multitude of translational applications with JAK inhibitors
1:45 pm Novel Strategies of Localized Drug Delivery to Re-Think the Application of JAK inhibitors
1:45 pm Novel Strategies of Localized Drug Delivery to Re-Think the Application of JAK inhibitors
Synopsis
- Developing a biocompatible lipid nanoformulation that encapsulate JAK inhibitors to achieve preferential targeting of the gut immune system following oral administration.
- Exploring a novel potential for JAK inhibitors as immunotherapeutics, rather than immunosuppressive drugs, in the treatment of autoimmunity and transplant rejection.
- Developing injectable hydrogels for localized and controlled release of JAK inhibitors and future advances.
2:15 pm FDA Perspective on JAK Inhibitor Development & Dermatologic Disorders
2:15 pm FDA Perspective on JAK Inhibitor Development & Dermatologic Disorders
Synopsis
- Considering what clinical endpoints the FDA will accept across multiple disciplines within JAK inhibitor drug development to accelerate delivery to market
- Q&A Time: An extended 15 minute session post presentation to alleviate all JAK inhibitor pipeline queries and save labor downstream